Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072

MYLAN INC (MYL)

63
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2014 12/12/2014 12/15/2014 12/16/2014 12/17/2014 Date
54.71(c) 53.32(c) 54.52(c) 53.56(c) 55.255(c) Last
2 540 644 3 291 836 3 553 198 2 563 828 3 198 664 Volume
-0.51% -2.54% +2.25% -1.76% +3.16% Change
More quotes
Company
Mylan, Inc. is a generic and specialty pharmaceuticals company, through its subsidiaries, which develops, manufactures, markets and distributes pharmaceuticals.The company operates its business through two segments: Generics & Specialty.The Generics segment primarily develops, manufactures, sells... 
Sector
Pharmaceuticals
Calendar
02/26Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | MYL | US6285301072 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 7 709 M
EBIT 2014 1 994 M
Net income 2014 1 206 M
Debt 2014 7 522 M
Yield 2014 -
Sales 2015 9 922 M
EBIT 2015 2 775 M
Net income 2015 1 958 M
Debt 2015 6 613 M
Yield 2015 -
PER 2014 19,20
PER 2015 15,01
EV / Sales 2014 3,66x
EV / Sales 2015 2,75x
Capitalization 20 680 M
More Financials
Latest news on MYLAN INC
7h ago MYLAN : Launches Generic Robaxin® Injection
1d ago MYLAN : World TeamTennis and Mylan Announce Title Sponsorship Extension Through ..
1d ago MYLAN : Patent Application Titled "Medicament Information System and Method" Pub..
1d ago Mylan Launches One of First Available Generic Versions of Celebrex® Capsules
1d ago MYLAN : Launches First Generic Version of Orapred ODT®
1d ago MYLAN : to Present at the J.P. Morgan 33rd Annual Healthcare Conference
7d ago Mylan launches generic version of Celebrex
12/11 MYLAN : Inversion to trigger early payday for Mylan executives
More news
Sector news
13m ago GSK shareholders approve asset swap deal with Novartis
24m ago PFIZER : Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Con..
48m ago France fines household product firms 951 million euro for price fixing
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF